These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9171199)

  • 1. Detection and interpretation of lysergic acid diethylamide results by immunoassay screening of urine in various testing groups.
    Wu AH; Feng YJ; Pajor A; Gornet TG; Wong SS; Forte E; Brown J
    J Anal Toxicol; 1997; 21(3):181-4. PubMed ID: 9171199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
    Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
    J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the diagnostic performance of the Boehringer Mannheim CEDIA LSD assay.
    Verstraete AG; Steyaert S
    J Anal Toxicol; 1998; 22(7):601-4. PubMed ID: 9847012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoassay analysis of lysergic acid diethylamide.
    Cody JT; Valtier S
    J Anal Toxicol; 1997 Oct; 21(6):459-64. PubMed ID: 9323526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An online immunoassay for LSD: comparison with GC-MS and the Abuscreen RIA.
    McNally AJ; Goc-Szkutnicka K; Li Z; Pilcher I; Polakowski S; Salamone SJ
    J Anal Toxicol; 1996 Oct; 20(6):404-8. PubMed ID: 8889676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction.
    Grobosch T; Lemm-Ahlers U
    J Anal Toxicol; 2002 Apr; 26(3):181-6. PubMed ID: 11991536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-oxo-3-hydroxy-LSD: an important LSD metabolite?
    Verstraete AG; Van de Velde EJ
    Acta Clin Belg; 1999; 53 Suppl 1():94-6. PubMed ID: 10216992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False-positive LSD testing in urine samples from intensive care patients.
    Röhrich J; Zörntlein S; Lotz J; Becker J; Kern T; Rittner C
    J Anal Toxicol; 1998 Sep; 22(5):393-5. PubMed ID: 9737335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of lysergic acid diethylamide in human urine: elimination, screening and analytical confirmation].
    Vu-Duc T; Vernay A; Calanca A
    Schweiz Med Wochenschr; 1991 Dec; 121(50):1887-90. PubMed ID: 1759150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a nonisotopic immunoassay for the detection of LSD in human urine.
    Cassells NP; Craston DH; Hand CW; Baldwin D
    J Anal Toxicol; 1996 Oct; 20(6):409-15. PubMed ID: 8889677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion interference with immunoassays for amphetamines and LSD.
    Vidal C; Skripuletz T
    Ther Drug Monit; 2007 Jun; 29(3):373-5. PubMed ID: 17529897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development and application of a gas chromatography-mass spectrometric (GC-MS) assay to determine the presence of 2-oxo-3-hydroxy-LSD in urine.
    Burnley BT; George S
    J Anal Toxicol; 2003; 27(4):249-52. PubMed ID: 12820748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid chromatography-electrospray ionization mass spectrometry for the detection of lysergide and a major metabolite, 2-oxo-3-hydroxy-LSD, in urine and blood.
    Sklerov JH; Magluilo J; Shannon KK; Smith ML
    J Anal Toxicol; 2000 Oct; 24(7):543-9. PubMed ID: 11043657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with testing for lysergic acid diethylamide.
    Ritter D; Cortese CM; Edwards LC; Barr JL; Chung HD; Long C
    Clin Chem; 1997 Apr; 43(4):635-7. PubMed ID: 9105265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
    Schwettmann L; Külpmann WR; Vidal C
    Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of lysergic acid diethylamide (LSD) in urine by gas chromatography-ion trap tandem mass spectrometry.
    Sklerov JH; Kalasinsky KS; Ehorn CA
    J Anal Toxicol; 1999 Oct; 23(6):474-8. PubMed ID: 10517553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD.
    Poch GK; Klette KL; Hallare DA; Manglicmot MG; Czarny RJ; McWhorter LK; Anderson CJ
    J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):23-33. PubMed ID: 10202954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of lysergide (LSD): the development of novel enzyme immunoassay and immunoaffinity extraction procedures together with an HPLC-MS confirmation procedure.
    Webb KS; Baker PB; Cassells NP; Francis JM; Johnston DE; Lancaster SL; Minty PS; Reed GD; White SA
    J Forensic Sci; 1996 Nov; 41(6):938-46. PubMed ID: 8914284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
    Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
    J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of LSD and a major metabolite, 2-oxo-3-hydroxy-LSD, in human urine by solid-phase extraction and gas chromatography-tandem mass spectrometry.
    Reuschel SA; Percey SE; Liu S; Eades DM; Foltz RL
    J Anal Toxicol; 1999 Sep; 23(5):306-12. PubMed ID: 10488916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.